Investigative Radiology

August 2016: Val M. Runge, MD, a note from the Editor
​This issue of the journal, as always, has many outstanding articles, representing cutting edge research and technology in diagnostic imaging. Articles involving both MR and CT are featured. Topics include several areas of high interest - imaging results at 7 T, advances in imaging technique on MR, and advances in CT (the latter specifically including an article describing single source dual energy CT with a split filter).​
Special Issue on 'Speed in MR'
Investigative Radiology will publish a special issue on 'Speed in MR' in 2017. The focus is on current significant advances in knowledge. Relevant topics include basic science investigations, clinical studies, and innovative clinical applications. With regard to clinical papers, all organ and disease areas will be considered. Submitted manuscripts should significantly advance our knowledge concerning methods (and applications therein) for increasing the speed with which data is acquired in MR together with innovative acquisition schemes that improve image quality. The focus of any submission does not necessarily need to be reduced scan time, which is simply one part of speed, with additional possible focuses including image quality, sensitivity, temporal and spatial resolution, and a decrease in image artifacts.

Manuscripts will be accepted for consideration beginning in October. The deadline for submission is January 31, 2017. All papers will be subject to peer review by experts in the field and must comply with the Journal's Instructions for Authors.

I look very much forward to receiving your submissions.

Best regards,

Val M. Runge, MD, Editor-in-Chief, Investigative Radiology ​

Current Issue Highlights

Actions
View
Actions
View

Editor-in-Chief:
Val M. Runge, MD

ISSN: 0020-9996

Online ISSN: 1536-0210

Frequency: 12 issues / year

Ranking: Radiology, Nuclear Medicine, and Medical Imaging 9/124

Impact Factor: 4.887

Safety of the Gadolinium-Based Contrast Agents, A Review
​This review discusses first the background in terms of development of these agents and safety discussions therein, and second their relative stability based both on in vitro studies and clinical observations before and including the advent of nephrogenic systemic fibrosis. This sets the stage for the subsequent focus of the review, the current knowledge regarding accumulation of gadolinium in the brain and specifically the dentate nucleus after intravenous administration of the GBCAs and differentiation among agents on this basis.​
Login